Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(4):295-313
Daptomycin is the first approved member of a cyclic lipopeptides class of antibiotics with anti-Gram(+) activity. In contrast to majority of other antimicrobials daptomycin has rapid bactericidal activity against not only rapidly growing, but also against slow growing bacterial cells including those in biofilms. Spectrum of daptomycin’s activity includes almost all clinically important Gram(+) microorganism. At the moment daptomycin is approved for two indications – complicated skin and skin structure infections at the dose of 4 mg/kg once daily, and bloodstream infections – bacteremia and right-sided endocarditis, caused by S. aureus. But at the same time there are a lot of clinical and experimental data showing that daptomycin could be an useful drug for the treatment of variety of other infections, such as bones and joints infections, febrile neutropenia, etc, especially those caused by multi-resistant strains. Taking into consideration clinical, pharmacological, and microbiological profile, as well as the situation with antimicrobial resistance, daptomycin should become an important option for the treatment of Gram(+) infections in Russia.